Litchman Manuel MD 4
4 · MUSTANG BIO, INC. · Filed Jun 4, 2024
Insider Transaction Report
Form 4
Litchman Manuel MD
DirectorPresident, CEO and Interim CFO
Transactions
- Tax Payment
Common Stock
2022-04-24$12.15/sh−1,248$15,163→ 80,992 total - Tax Payment
Common Stock
2023-04-24$4.21/sh−1,572$6,618→ 79,420 total
Footnotes (4)
- [F1]1,248 shares of common stock were relinquished to cover tax liability associated with the delivery of shares of common stock upon the vesting of restricted stock units.
- [F2]The amount of common stock reflected on this Form 4 has been adjusted to reflect a 1-for-15 reverse stock split that occurred subsequent to this transaction.
- [F3]1,572 shares of common stock were relinquished to cover tax liability associated with the delivery of shares of common stock upon the vesting of restricted stock units.
- [F4]Includes 3,975 shares of common stock acquired under the Mustang Bio, Inc. Employee Stock Purchase Plan on March 1, 2023 and September 1, 2023.